
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune is a clinical stage biopharmaceutical company that specializes in developing precision medicine for neurodegenerative diseases. Their pipeline consists of several promising candidates, including ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, and ACI-7104.056, all targeting misfolded proteins associated with neurodegeneration. The company's partnerships with major pharmaceutical companies, such as Takeda and Eli Lilly, provide a strong foundation for future success. The recent promising readouts for its AD and PD programs, along with a strong cash position expected to fund operations through 2027, make AC Immune a strong investment opportunity in the biopharmaceutical sector.
Bears say
AC Immune is heavily reliant on the success of their pipeline, particularly the ACI-24.060 and Crenezumab treatments for Alzheimer's disease, with upcoming data releases in 1H26. While promising immunogenicity data has been seen for the ACI-24 vaccine, the lack of ARIA-E events in the trial is concerning and could potentially hinder the clinical efficacy of the treatment. Additionally, the company's focused resources on targeting misfolded proteins may limit their potential for diversification and put them at risk if there are any setbacks in their pipeline.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares